October 7, 2008 - KC BioMedix, a rapidly advancing medical device company that specializes in providing solutions for neonatal feeding problems, and Open Prairie Ventures, an early-stage venture capital firm specializing in medical, agricultural and IT technologies, announced today the firm has made an investment in KC BioMedix’s Series A financing. Along with the investment, Michael Peck, Partner at Open Prairie Ventures, a 10 year early-stage investment and entrepreneurial veteran, will join the Board of Directors for KC BioMedix.

  
KC BioMedix has raised $4 million to date; including $1.5 million in a previous undisclosed seed round. The new Series A capital will be used to expand the growth of the company and initiate product sales in 2009.  This investment represents the fourth investment of Open Prairie Ventures II, LP.

“We believe KC BioMedix and its experienced management team fit perfectly within our strategy and investment thesis. The company has been a technology innovator while demonstrating an efficient approach to building a sustainable company.” said Peck. “The company has set a great example of how to take university-based technologies, leverage the accelerators and seed capital to produce a marketable product.”

D. Michael Litscher, a co-founder and CEO of KCBioMedix said, “Our first product the NTrainer System®, recently cleared by the FDA for marketing, has benefited from the research at the University of Kansas and the business assistance environment in Kansas. We are now delighted to add Open Prairie Ventures as an investor and partner. The Open Prairie Ventures team has a great deal of experience in the medical device technology sector and with growing early-stage companies.

For more information about KC BioMedix or its neonatal medical devices, please visit their website, www.kcbiomedix.com or contact Barry Price at bprice@kcbiomedix.com. For more information about Open Prairie Ventures, please visit their website, www.openprairie.com.